Abstract
Chronic wounds, often accompanied by bacterial infection, pose significant clinical challenges. Recognizing this, there has been a growing interest in leveraging nucleic acids as intelligent materials for targeted cargo delivery. Herein, we introduced a pioneering method for encapsulating the anti-S. aureus peptide NZ2114 and epidermal growth factors (EGF) within crosslinked DNA nanomaterials, creating biodegradable and biocompatible antimicrobial agents with high efficacy. Our research validated that the NZ2114-EGF-Gel could exhibit a specific inhibitory effect on S. aureus growth while simultaneously accelerating human dermal fibroblasts’ proliferation. The crosslinked DNA nanostructures demonstrate an enhanced capacity to promote wound therapy rates during in vivo treatment. These findings present a prospective avenue for facilitating therapeutic wound healing.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
